NCT00318500

Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 75 mg and 150 mg Doses of ERB-041 on the Reduction of Symptoms Associated With Endometriosis During Treatment and Post Treatment in Reproductive-Aged Women

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 150 (planned)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the efficacy and safety of two doses of ERB-041 (75 mg and 150 mg) relative to placebo on the relief of endometriosis-related symptoms (dysmenorrhea, pelvic pain, and deep dyspareunia) in reproductive aged women.

Conditions

• Dysmenorrhea
• Dyspareunia
• Endometriosis
• Pelvic Pain

Interventions

Type	Name	Description
DRUG	ERB-041

Timeline

• Start date: 2006-05-01
• Completion: 2006-12-01
• First posted: 2006-04-26
• Last updated: 2007-12-10

Locations

70 sites across 7 countries: United States, Australia, Belgium, Canada, Hong Kong, South Africa, United Kingdom